Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1478-3231.2007.01534.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of Enfortumab-Vedotin for Right Atrial Metastasis Following Total Cystectomy: A Case Report.
Cureus
December 2024
Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, JPN.
Cardiac metastases from bladder cancer are extremely rare and typically associated with a poor prognosis. We here report a case of a 74-year-old woman who had been diagnosed with multiple bladder cancer and later developed pelvic recurrence and multiple bone metastases. Second-line pembrolizumab treatment achieved complete remission.
View Article and Find Full Text PDFOutcomes of Combined Atezolizumab Plus Chemotherapy in Non-small Cell Lung Cancer Patients in Clinical Practice.
Cancer Diagn Progn
January 2025
Division of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Background/aim: Atezolizumab, one of the anti-PD-L1 antibodies, targets PD-L1 expressed on cancer cells and antigen-presenting cells. This immune checkpoint inhibitor is now commonly used in combination with chemotherapy. The objectives of this study were to confirm the treatment outcomes of combined atezolizumab plus chemotherapy, and to identify prognostic factors, with a particular focus on the impact of the site of metastasis in real-world clinical practice.
View Article and Find Full Text PDFSingle-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).
Radiat Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan.
Article Synopsis
- This study explored the effectiveness and safety of combining chemoradiotherapy (CRT) with local consolidative therapy (LCT) for patients with Stage IV non-small cell lung cancer (NSCLC) and oligometastases.
- During the Phase II trial involving 19 patients, the treatment resulted in a 58% response rate, median progression-free survival of 8.6 months, and a two-year survival rate of 68.4%.
- The findings suggest that this aggressive treatment approach may prolong survival and improve local control without severe adverse events.
Successful thoracoscopic-assisted resection of a functional paraganglioma in the mediastinum with extracorporeal circulation: a case report.
J Cardiothorac Surg
January 2025
Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P. R. China.
Background: Paragangliomas are rare neoplasms arising from extra-adrenal chromaffin cells, with mediastinal paragangliomas representing an exceptionally rare subset. This report details the surgical management of a complex mediastinal paraganglioma case, presenting with refractory hypertension and invasion of critical surrounding structures. A comprehensive review of the current literature is included to underscore existing cases, enhance clinical awareness, and share our insights and experience in the diagnosis and treatment of this challenging condition.
View Article and Find Full Text PDFIntroduction: Adrenal myelolipomas are uncommon benign adrenal tumors, which mostly occur unilaterally. We describe a rare case of giant bilateral adrenal myelolipoma mistaken for retroperitoneal liposarcoma.
Case Presentation: A 49-year-old man developed fever, left flank pain, and a large mass in his left abdomen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!